| Literature DB >> 34148949 |
Takeshi Miura1, Shoji Saito2,3, Rie Saito2, Tomohiro Iwasaki4, Naomi Mezaki1, Tomoe Sato1, Yoichi Ajioka5, Akiyoshi Kakita2, Takuya Mashima1.
Abstract
Intravascular large B-cell lymphoma (IVLBCL) is a subtype of B-cell lymphoma, characterized by lymphoma cell proliferation within small blood vessels. We herein describe a rare case with long spinal cord lesions caused by venous congestive myelopathy associated with IVLBCL. An 81-year-old man presented with paraplegia of the lower limbs and sensory disturbances. Magnetic resonance imaging revealed intramedullary longitudinal T2-hyperintensity lesions in the thoracic cords. The patient died three months after disease onset, and a neuropathological analysis revealed predominantly atypical B-lymphocytes located sparsely in the veins of the spinal cord. IVLBCL should be considered in the differential diagnoses of long spinal cord lesions.Entities:
Keywords: IVL; IVLBCL; MALT lymphoma; intravascular lymphoma; long spinal cord lesion; venous congestive myelopathy
Mesh:
Year: 2021 PMID: 34148949 PMCID: PMC8710383 DOI: 10.2169/internalmedicine.6717-20
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure 1.1.5 Tesla magnetic resonance imaging (MRI) of the spinal cord. a: On the first hospital day, T2-weighted image (T2WI, the left panel) shows an intramedullary lesion with high signal intensity at the T3 to T6 level. b: The second MRI 10 days after admission. T2WI hyperintensity lesions tend to expand and split between T3 to T4 and T5 to T6. c: The third MRI on the 18th day after admission. T2WI (the left panel) reveals that the hyperintensity lesions remain unchanged and gadolinium-enhanced T1WI (the right panel) demonstrates abnormal mild gadolinium enhancement on the dorsal edge of T4 to T5. d: The fourth MRI on the 44th day after admission. The T2WI (the left panel) shows that the hyperintensity lesions further expand and divide into the upper part of C7 to T4 and the lower part of T4 to T9. The gadolinium enhancement T1WI (the right panel) demonstrates the faint enhancement effect on the height of T4 to T5.
Laboratory Data on Admission and 12 Days after Admission.
| On admission | 12 days after admission | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| |||||||||
| WBC (4-9×103/µL) | 4.940 | TP (6.5-8.3 g/dL) | 6.7 | |||||||
| Differential count*1 | ALB (3.9-4.9 g/dL) | 3.3 | ALB | 2.0 | ||||||
| Neutrophils (42-74%) | 61.0 | AST (8-38 U/L) | 36 | AST | 47 | |||||
| Eosinophils (0-7%) | 1.0 | ALT (4-43 U/L) | 22 | ALT | 41 | |||||
| Basophils (0-2%) | 0.0 | LDH (106-211 U/L) | 299 | LDH | 162 | |||||
| Monocytes (1-8%) | 12.0 | ALP (103-335 U/L) | 200 | ALP | 186 | |||||
| Lymphocytes (18-50%) | 26.0 | γGTP (13-66 U/L) | 15 | |||||||
| RBC (431-565×104/µL) | 494 | T-bil (0.2-1.2 mg/dL) | 1.1 | T-bil | 0.6 | |||||
| Hb (13.7-17.4 g/dL) | 11.1 | CK (61-225 U/L) | 80 | |||||||
| Ht (40.2-51.5%) | 33.3 | BUN (9-23 mg/dL) | 17.7 | BUN | 13.7 | |||||
| MCV (83-101 fL) | 95.2 | Cre (0.6-1.1 mg/dL) | 0.41 | Cre | 0.56 | |||||
| MCH (28.1-34.5 pg) | 31.7 | UA (3-7 mg/dL) | 3.6 | |||||||
| MCHC (31.9-34.7 g/dL) | 33.3 | CRP (<0.1 mg/dL) | 5.43 | |||||||
| Plt (13-38×104/uL) | 3.9 | Anti-AQP4 antibody*2 | (-) | β2MG (0.9-2.0 mg/dL) | 2.3 | |||||
| Anti-MOG antibody*3 | (-) | sIL-2R (122-496 U/mL) | 7,901 | |||||||
The range of normal values are given in parenthesis.
WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, MCV: mean corpusclular volume, MCH: mean corpusclular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, Plt: platelet, TP: total protein, ALB: albumin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γGTP: gamma-glutamyltransferase, T-bil: total bilirubin, CK: creatine kinase, BUN: blood urea nitrogen, Cre: creatinine, CRP: C-reactive protein, AQP4: aquaporin4, MOG: myelin-oligodendrocyte glycoprotein, β2MG: β2 micro globulin, sIL-2R: soluble interleukin 2 receptor
*1 Leukocyte differential count was based on visual inspection. All of neutrophils were segmented neutrophils.
*2 anti-AQP4 antibody was measured by enzyme-linked immunosorbent assay (ELISA) and cell-based assay.
*3 anti-MOG antibody was measured by cell-based assay.
Figure 2.The endoscopic findings and gastric mucosa biopsy findings. a: Esophagogastroduodenoscopy 67 days after admission reveals the growth of the edematous mucosal lesion (arrow). b: The tumor cells with increasing size and cellularity with a high nuclear-to-cytoplasmic ratio [Hematoxylin and Eosin (H&E) staining, ×10]. c: Evident nuclear atypia (H&E staining, ×40). d: The tumor cells with CD20-immunoreactivity (CD20, ×20). e: Ki-67 labeling index over 50% (Ki-67, ×20). Scale bar: 100 μm in b.
Figure 3.A summary of the patient’s clinical course. The patient died 77 days after admission, approximately 3 months after onset. AMPC: amoxicillin, BMA: bone marrow aspiration, CM: clarithromycin, CPA: cardiopulmonary arrest, EGD: esophagogastroduodenoscopy, LDH: lactate dehydrogenase, mPSL: methylprednisolone, P-CAB: vonoprazan, RBC: red blood cell, sIL-2R: soluble interleukin-2 receptor, u: unit, β2MG: β2-microglobulin
Figure 4.Histopathologic features of the spinal cord in the studied patient. a: Fixed sections showing extensive and multifocal lesions with hemorrhage from T3 to S1 segments. Note severely affected lesions of the thoracic cord. Macroscopically, no hemorrhagic lesion appears above the level of T2. b: Semi macroscopic features subjected to Klüver-Barrera (KB) staining. Focal lesion of the left lateral column and Wallerian degeneration of the bilateral gracile fasciculus (arrows) in T3. Multifocal lesions in the gray and white matter in T6. i: Focal necrosis, ii: Gray matter hemorrhage, iii: Peripheral vacuolation, iv: Diffuse necrosis [KB, ×1.25, i-iv, Hematoxylin and Eosin (H&E) staining, ×10]. c, d: Some CD20-positive atypical B-lymphocytes within the lumen of the spinal intramedullary vein (c: H&E staining, ×20, d: CD20, ×20). e: A vein in the subarachnoid space with fibrous thickening and obstruction (H&E staining, ×10). Scale bar: 4 mm in a, 1.5 mm in b, 100 μm in i–iv, 25 μm in c and d; 50 μm in e.
Pathological Findings of the Spinal Cord in the Studied Patient.
| Arteriogenic feature | Venousgenic features | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Level* | Focal necrosis | Diffuse necrosis | Gray matter hemorrhages | Peripheral vacuolation | |||||
| C7 | - | - | - | ++ | |||||
| T3 | +; lt. Lateral column | - | +++ | +++ | |||||
| T4 | +; lt. Lateral column | - | +++ | +++ | |||||
| T5 | +; lt. Lateral column | - | +++ | +++ | |||||
| T6 | - | + | Not available** | +++ | |||||
| T7 | - | + | Not available** | +++ | |||||
| T9 | - | - | +++ | ++ | |||||
| T10 | - | - | +++ | ++ | |||||
| L2 | - | - | + | + | |||||
| L3 | - | - | ++ | ++ | |||||
| L4 | +rt. Posterior horn | - | ++ | +++ | |||||
| S1 | +rt. Posterior horn | - | ++ | ++ | |||||
| S2 | - | - | + | ++ | |||||
| S3 | - | - | + | ++ | |||||
The presence or absence of focal necrosis and diffuse necrosis was expressed as "+" or "-", respectively.
The severity of gray matter hemorrhages and peripheral vacuolation were graded according to the semiquantitative evaluation: none:-, mild:+, moderate:++, severe:+++.
* Spinal cord level, microscopically examined,
** Gray matter was not available due to severe destruction caused by diffuse necrosis.
Clinicopathological Features of Reported Cases of Intravascular Lymphoma Presenting Long Spinal Cord Lesions *1.
| Case no. | Reference | Age (years)/ | Symptoms | Lesion / length (no. of vertebral bodies) | Clinical diagnosis | Disease course | Serum LDH initial/ | Serum sIL-2R initial (U/mL) | Treatments (efficacy) | Time from onset to diagnosis of IVLBCL (months) | Overall survival (months) | Definite diagnostic method | Possible etiology of myelopathy/ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (3) | 41/M | Conus medullaris syndrome | Conus medullaris/ 3 | Acute inflammatory demyelinating disease | Subacute | → / ND | ND | mPSL (-)*2
| 13 | 13 | Autopsy | Infarct |
| 2 | (4) | 52/M | Paraplegia, urinary incontinence | T-L/>9 | Asian variant of IVLBCL | Subacute | 325 / 737 | 13,700 | R-CHOP (+) | 4 | Over 42 | Muscle, nasal polyps and bone marrow biopsy | ND |
| 3 | (5) | 82/F | Lower limbs weakness, numbness | T/ 7 | Transverse myelitis | Subacute | → / 488 | ND | mPSL (-), | 14 | 14 | Autopsy | Congestion |
| 4 | (6) | 45/M | Lower limbs dysesthesia, paraplegia | T-L/ 17 | Immune-mediated myelopathy / IVLBCL | Subacute | 283 / ND | 2,666 | mPSL (-) | 14 | Over 26 | Renal biopsy | Infarct, immune-mediated (demyelination) |
| 5 | (7) | 64/F | Lower limbs paraplegia, sensory disturbance | T/ 8 | IVLBCL | Subacute | 382 / ND | 1,670 | mPSL (-) | 4.5 | Over 5 | Random skin biopsy | ND |
| 6 | (8) | 82/F | Paraplegia | C-T/ 11 | Myelopathy, intracranial hemorrhages / IVLBCL | Subacute | ND / ND | ND | ND | ND | ND | Random skin biopsy | ND |
| 7 | Present case | 81/M | Lower limbs paraplegia, sensory disturbance, urinary retention | C-T/ 10 | Infarction, Transverse myelitis | Subacute | 299*4/ 455 | 7,901 | anti-platelet (-), | 3 | 3 | Autopsy | Infarct, venous congestion |
*1 Long spinal cord lesions are defined as 3 or more vertebral segment longitudinally lesions.
*2 The cerebrospinal fluid results improved but the symptoms remained unchanged.
*3 Clinical symptoms as well as CSF parameters and radiologic findings improved slightly.
*4 Decreased to the normal range before mPSL treatment
→: documented as normal range, (+): effective, (-): ineffective, C: cervical, CPA: cyclophosphamide, F: Female, IVLBCL: intravascular large B-cell lymphoma, L: lumbar, M: Male, mPSL: methylprednisolone, ND: Not documented, PE: plasma exchange, R-CHOP: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, T: thoracic